Mechanism of Action

Treating diabetes using menin inhibitors to regenerate insulin producing beta-cells

 

Type 2 Diabetes: A Rapidly Growing Disease

According to the Centers for Disease Control and Prevention (CDC), 1 in 10 Americans have been diagnosed with Type 2 Diabetes (T2D), costing $174 billion a year in 2007. If present trends continue, 1 in 3 will suffer from T2D by the year 2050. In 2011, the average medical cost per person with T2D was almost $7,000 a year, equating to almost half a million dollars in one’s lifetime. With healthcare costs projected to increase threefold, that number will continue to accelerate.

A Novel Solution: Maximizing Endogenous Insulin Output

Novapeutics uses a patent pending approach to develop treatments for type 2 diabetes by using menin inhibitors. The Novapeutics approach will increase the number of functional pancreatic beta-cells while reducing stress in beta-cells, resulting in overall maximum endogenous insulin output in diabetic patients.

Mechanism of Action

novapeutics_mechanism_of_actionSelective inhibition of the menin/MLL (mixed lineage leukemia-1) interaction, which promotes beta cell mass and insulin production increase.

Drug Screening Platform

novapeutics_drug_screening_platformNovapeutics’ unique proprietary screening platform identified two compounds, CDH1 and CDH2, which inhibit the menin/MLL interaction. Further development is underway.

Proof of Concept

novapeutics_proof_of_conceptMurine model of diabetes:

  • MEN1 gene excision significantly increases pancreatic beta-cell mass in islets
  • MEN1 deletion increases insulin production